All In Biotech

Drug Trial Radar · NCT05656027

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 469 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

469

Actual

Start

Dec 19, 2022

Primary completion

Dec 15, 2023

Study completion Jan 25, 2024

Sponsor

Lead sponsor
LENZ Therapeutics, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.

Conditions

  • Presbyopia
  • Refractive Error
  • Eye Diseases
  • Near Vision

Interventions

  • Aceclidine+Brimonidine combination ophthalmic solutionDrug

    LNZ101 (Aceclidine/Brimonidine) ophthalmic solution

  • Aceclidine ophthalmic solutionDrug

    LNZ100 Aceclidine ophthalmic solution

  • BrimonidineDrug

    Brimonidine ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 3 hours post-treatment in the study eye on Day 1

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site #106

    Chandler, Arizona

  • Site #121

    Mesa, Arizona

  • Site #122

    Phoenix, Arizona

  • Site #124

    Phoenix, Arizona

  • Site #128

    Scottsdale, Arizona

  • Site #125

    Sun City, Arizona

  • Site #130

    Azusa, California

  • Site #110

    Garden Grove, California

  • Site #101

    Glendale, California

  • Site #129

    Newport Beach, California

  • Site #107

    Petaluma, California

  • Site #126

    Rancho Cordova, California

  • Site #111

    Santa Barbara, California

  • Site #109

    Littleton, Colorado

  • Site #102

    Mt. Dora, Florida

  • Site #118

    Rock Island, Illinois

  • Site #127

    Overland Park, Kansas

  • Site #108

    Pittsburg, Kansas

  • Site #131

    Rochester, New York

  • Site #104

    Fargo, North Dakota

  • Site #103

    Kingston, Pennsylvania

  • Site #116

    Memphis, Tennessee

  • Site #112

    Smyrna, Tennessee

  • Site #119

    San Antonio, Texas

  • Site #123

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.